Seoul, South Korea

Jie Young Song

This inventor holds 5 USPTO granted patents and 8 published patent applications and 2 EPO patents. Top assignee: Korea Institute of Radiological & Medical Sciences. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jie Young Song. Retrieved from https://idiyas.com/inventor/jie-young-song

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Goyang-si, KR (2015 - 2016)
  • Seoul, KR (2020 - 2024)

Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Jie Young Song in Cancer Treatment and Obesity Prevention

Introduction

Jie Young Song is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the fields of cancer treatment and obesity prevention through his innovative pharmaceutical compositions. With a total of five patents to his name, his work is recognized for its potential impact on health and medicine.

Latest Patents

One of Jie Young Song's latest patents is a pharmaceutical composition for preventing or treating cancer, which contains N-1H-benzimidazol-2-yl-3-(1H-pyrrole-1-yl)benzamide as the active ingredient. This invention focuses on a composition that not only prevents the proliferation of cancer cells by arresting their mitosis but also exhibits low toxicity in normal cell lines. It induces apoptosis specifically in cancer cell lines, making it a promising anticancer agent. Additionally, this compound enhances the sensitivity of treated cancer cells to radiation, positioning it as a valuable radiosensitizer for cancer treatment.

Another notable patent addresses obesity treatment and prevention. The invention revolves around Melanophilin (MLPH), which plays a crucial role in adipocyte differentiation and fat accumulation. By inhibiting MLPH, obesity can be effectively treated or prevented. Furthermore, measuring the expression level of MLPH allows for the diagnosis and treatment of obesity, as well as the screening of therapeutic agents that regulate adipocyte differentiation.

Career Highlights

Jie Young Song is affiliated with the Korea Institute of Radiological & Medical Sciences, where he conducts his research and development. His work is characterized by a strong focus on innovative solutions to pressing health issues, particularly in oncology and metabolic disorders.

Collaborations

Some of his notable coworkers include Hee Chung Kwon and Ji Yeon Ahn, who contribute to the collaborative efforts in advancing research and development in their respective fields.

Conclusion

Jie Young Song's innovative contributions to cancer treatment and obesity prevention highlight his role as a leading inventor in the pharmaceutical industry. His patents reflect a commitment to developing effective solutions that address critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…